Incorporación al Plan Médico Obligatorio del tratamiento con análogos de la hormona liberadora de gonadotrofinas (aGnRH) para la pubertad precoz central

Costanzo, Mariana; Arcari, Andrea; Keselman, Ana; Alonso, Guillermo; Pipman, Viviana R; Martin, Silvia; D'Amato, Silvia; Rodríguez Azrak, María Sol; Boulgourdjian, Elizabeth María.
Arch. argent. pediatr ; 120(2): e122-e122, abril 2022.
Artículo en Español | LILACS, BINACIS | ID: biblio-1363829

Documentos relacionados

  1. [Considerations on the improvement of height benefit in children with central precocious puberty].
  2. Diagnosis and management of precocious sexual maturation: an updated review.
  3. Early Puberty.
  4. [Further progress of the etiology,diagnosis and treatment of peripheral precocious puberty].
  5. The functional study of a novel MKRN3 missense mutation associated with familial central precocious puberty.
  6. [Recent advances in the genetic etiology of central precocious puberty].
  7. Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.
  8. Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis.
  9. Gonadotropin-Releasing Hormone Analogs for Treatment of Central Precocious Puberty in Children Younger than 2 Years of Age.
  10. Basal gonadotropin levels combine with pelvic ultrasound and pituitary volume: a machine learning diagnostic model of idiopathic central precocious puberty.